Rothwell PM. External validity of randomised controlled trials: “to whom do the results of this trial apply?” The Lancet. 2005;365(9453):82–93.

Article  Google Scholar 

Ayaz A, Naqvi SAA, Islam M, Ikram W, Raza U, Riaz A, et al. Source of funding and enrollment disparities in the inclusion of minorities in colorectal clinical trials: a systematic review and meta-analysis. Journal of Clinical Oncology. 2023;41(4_suppl):23–23.

Article  Google Scholar 

• Batra A, Kong S, Cheung WY. Eligibility of real-world patients with stage ii and iii colon cancer for adjuvant chemotherapy trials. Clin Colorectal Cancer. 2020;19(4):e226-34. Study that evaluates and reflects on the eligibility of real-world patients for colorectal cancer adjuvant chemotherapy trials.

Article  PubMed  Google Scholar 

Subbiah V, Solit DB, Chan TA, Kurzrock R. The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians. Ann Oncol. 2020;31(9):1115–8.

Article  CAS  PubMed  Google Scholar 

• Del Paggio JC, Berry JS, Hopman WM, Eisenhauer EA, Prasad V, Gyawali B, et al. Evolution of the randomized clinical trial in the era of precision oncology. JAMA Oncol. 2021;7(5):728. Retrospective cohort study that describes trends over time in the design, funding, and results of randomized controlled trials in oncology.

Article  PubMed  Google Scholar 

Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106(1):36–9.

Article  PubMed  PubMed Central  Google Scholar 

Relton C, Torgerson D, O’Cathain A, Nicholl J. Rethinking pragmatic randomised controlled trials: introducing the “cohort multiple randomised controlled trial” design. BMJ. 2010;340(mar191):c1066–c1066.

Article  PubMed  Google Scholar 

Li G, Sajobi TT, Menon BK, Korngut L, Lowerison M, James M, et al. Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research? J Clin Epidemiol. 2016;80:16–24.

Article  PubMed  Google Scholar 

•• Saesen R, Van Hemelrijck M, Bogaerts J, Booth CM, Cornelissen JJ, Dekker A, et al. Defining the role of real-world data in cancer clinical research: the position of the European Organisation for Research and Treatment of Cancer. Eur J Cancer. 2023;186:52–61. Perspective of the European Organisation for Research and Treatment of Cancer (EORTC) on use of real-world data in cancer clinical research.

Article  PubMed  Google Scholar 

Saesen R, Kantidakis G, Marinus A, Lacombe D, Huys I. How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer. Front Pharmacol. 2022;24:13.

Google Scholar 

US Food and Drug Administration. Framework for FDA’s real world evidence program. 2018. Available at: https://www.fda.gov/media/120060/download. Accessed 12 Sep 2023.

 European Medicines Agency. Real-world evidence framework to support EU regulatory decision-making. Reference EMA/289699/2023. 2023. Available at: https://www.ema.europa.eu/en/documents/report/real-world-evidence-framework-support-eu-regulatory-decision-making-report-experience-gained-regulator-led-studiesseptember-2021-february-2023_en.pdf. Accessed 12 Sep 2023.

Punt CJA, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14(4):235–46.

Article  CAS  PubMed  Google Scholar 

Iversen LH, Green A, Ingeholm P, Østerlind K, Gögenur I. Improved survival of colorectal cancer in Denmark during 2001–2012 – the efforts of several national initiatives. Acta Oncol (Madr). 2016;55(sup2):10–23.

Article  Google Scholar 

Iversen LH, Ingeholm P, Gögenur I, Laurberg S. Major reduction in 30-day mortality after elective colorectal cancer surgery: a nationwide population-based study in Denmark 2001–2011. Ann Surg Oncol. 2014;21(7):2267–73.

Article  PubMed  Google Scholar 

Brouwer NPM, Bos ACRK, Lemmens VEPP, Tanis PJ, Hugen N, Nagtegaal ID, et al. An overview of 25 years of incidence, treatment and outcome of colorectal cancer patients. Int J Cancer. 2018;143(11):2758–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023. CA Cancer J Clin. 2023;73(3):233–54.

Article  PubMed  Google Scholar 

Holleczek B, Rossi S, Domenic A, Innos K, Minicozzi P, Francisci S, et al. On-going improvement and persistent differences in the survival for patients with colon and rectum cancer across Europe 1999–2007 – results from the EUROCARE-5 study. Eur J Cancer. 2015;51(15):2158–68.

Article  PubMed  Google Scholar 

Lundberg FE, Birgisson H, Johannesen TB, Engholm G, Virtanen A, Pettersson D, et al. Survival trends in patients diagnosed with colon and rectal cancer in the nordic countries 1990–2016: the NORDCAN survival studies. Eur J Cancer. 2022;172:76–84.

Article  PubMed  Google Scholar 

• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325(7):669–85. Comprehensive review on treatment options for metastatic colorectal cancer.

Article  CAS  PubMed  Google Scholar 

Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, et al. TRIBE2: upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase. Lancet Oncol. 2020;21(4):497–507.

Article  CAS  PubMed  Google Scholar 

• Shen C, Tannenbaum D, Horn R, Rogers J, Eng C, Zhou S, et al. Overall survival in phase 3 clinical trials and the surveillance, epidemiology, and end results database in patients with metastatic colorectal cancer, 1986–2016. JAMA Netw Open. 2022;5(5):e2213588. Systematic review on the factors associated with clinically relevant improvement (defined as 2 months) in overall survival of mCRC patients in trials, and the association with outcomes reflected in SEER registry data.

Article  PubMed  PubMed Central  Google Scholar 

Zeineddine FA, Zeineddine MA, Yousef A, Gu Y, Chowdhury S, Dasari A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. NPJ Precis Oncol. 2023;7(1):16.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ellis L, Woods LM, Estève J, Eloranta S, Coleman MP, Rachet B. Cancer incidence, survival and mortality: explaining the concepts. Int J Cancer. 2014;135(8):1774–82.

Article  CAS  PubMed  Google Scholar 

Feinstein AR, Sosin DM, Wells CK. The Will Rogers Phenomenon. N Engl J Med. 1985;312(25):1604–8.

Article  CAS  PubMed  Google Scholar 

•• Templeton AJ, Booth CM, Tannock IF. Informing patients about expected outcomes: the efficacy-effectiveness gap. Journal of Clinical Oncology. 2020;38(15):1651–4. Commentary on the existence and relevance of the efficacy-effectiveness gap.

Article  PubMed  Google Scholar 

Jin S, Pazdur R, Sridhara R. Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015. J Clin Oncol. 2017;35(33):3745–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Westgeest HM, Uyl-de Groot CA, van Moorselaar RJA, de Wit R, van den Bergh ACM, Coenen JLLM, et al. Differences in trial and real-world populations in the Dutch Castration-resistant Prostate Cancer Registry. Eur Urol Focus. 2018;4(5):694–701.

Article  PubMed  Google Scholar 

Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, et al. Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol. 2013;24(12):2972–7.

Article  CAS  PubMed  Google Scholar 

Mol L, Koopman M, van Gils CWM, Ottevanger PB, Punt CJA. Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. Acta Oncol (Madr). 2013;52(5):950–5.

Article  Google Scholar 

Truong J, Lee EK, Trudeau ME, Chan KKW. Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):608–18.

Article  CAS  PubMed  Google Scholar 

Schnipper LE, Davidson NE, Wollins DS, Blayney DW, Dicker AP, Ganz PA, et al. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–34.

Article  PubMed  Google Scholar 

Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Annals of Oncology. 2017;28(10):2340–66.

Article  CAS  PubMed  Google Scholar 

Vogler S, Alexander M, Dedet G, Lam J, Bak Pedersen H. World Health Organisation - Medicines Reimbursement Policies in Europe. 2018. Available at: https://iris.who.int/bitstream/handle/10665/342220/9789289053365-eng.pdf?isAllowed=y&sequence=1. Accessed 22 Oct 2023.

Grothey A, Van CE, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 2013;381(9863):303–12.

Article  CAS  Google Scholar 

Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909–19.

Article  PubMed  Google Scholar 

Makady A, ten Ham R, de Boer A, Hillege H, Klungel O, Goettsch W. Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies. Value in Health. 2017;20(4):520–32.

Article  PubMed  Google Scholar 

Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E–mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON study. J Clin Oncol. 2021;39(4):273–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

• Cervantes A, Adam R, Roselló S, Arnold D, Normanno N, Taïeb J, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology. 2023;34(1):10–32. The most recent ESMO treatment guideline for metastatic colorectal cancer.